Amino acid compositions and methods for the treatment of liver diseases

A composition comprising:

• a) a L-amino acid entity chosen from:
• i) L-leucine or a salt thereof,
• ii) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-leucine, or
• iii) β-hydroxy-β-methylbutyrate (HMB) or a salt thereof;
• b) an R-amino acid entity chosen from:
• i) L-arginine or a salt thereof,
• ii) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-arginine,
• iii) ornithine or a salt thereof,
• iv) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising ornithine,
• v) creatine or a salt thereof, or
• vi) a dipeptide or salt thereof, or tripeptide or salt thereof, comprising creatine;
• c) L-glutamine or a salt thereof or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising L-glutamine;
• d) N-acetylcysteine (NAC) or a salt thereof or a dipeptide or salt thereof, or tripeptide or salt thereof, comprising NAC;
• and
• e) one or more excipients chosen from one, two, three, four, or five of a buffering agent, a sweetener, a dispersion enhancer, a flavoring agent, or a coloring agent;
• wherein when the leucine amino acid entity is HMB, the arginine amino acid entity is not creatine, and when the arginine amino acid entity is creatine, the leucine amino acid entity is not HMB;
• wherein, when the composition is in powder form, at least 50 wt. % of the total wt. of the composition is one or more amino acid entities in free form, and
• wherein the total wt. % of (a)-(d) is greater than the total wt. % of other amino acid entities in the composition.

A composition comprising:

• a) L-leucine or a salt thereof;
• b) L-arginine or a salt thereof;
• c) L-glutamine or a salt thereof;
• d) NAC or a salt thereof;
• e) L-isoleucine or a salt thereof;
• f) L-valine or a salt thereof;
• and
• g) one or more excipients chosen from one, two, three, four, or five of a buffering agent, a sweetener, a dispersion enhancer, a flavoring agent, or a coloring agent;
• wherein, when the composition is in powder form, at least 50 wt. % of the total wt. of the composition is one or more amino acid entities in free form, and
• wherein the total wt. % of (a)-(d) is greater than the total wt. % of other amino acid entities in the composition.

A method of manufacturing or making a composition comprising forming a composition comprising the following:

• a) a leucine (L)-amino acid entity chosen from L-leucine, oxo-leucine, β-hydroxy-β-methylbutyrate (HMB), isovaleryl-CoA, or N-acetyl-leucine;
• or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
• b) an arginine (R)-amino acid entity chosen from L-arginine, argininosuccinate, L-citrulline, L-aspartate, L-glutamate, L-ornithine, agmatine, creatine, or N-acetyl-arginine;
• or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
• c) a glutamine (Q)-amino acid entity chosen from L-glutamine, L-glutamate, carbamoyl-P, or N-acetyl-glutamine;
• or a salt thereof, a dipeptide or salt thereof, a tripeptide or salt thereof, or a combination of any of the aforesaid;
• d) N-acetylcysteine (NAC) or a salt thereof, a dipeptide or salt thereof, or a combination of any of the aforesaid;
• and
• e) one or more excipients chosen from a buffering agent, a sweetener, a dispersion enhancer, a flavoring agent, and a coloring agent;
• wherein when the leucine amino acid entity is HMB, the arginine amino acid entity is not creatine, and when the arginine amino acid entity is creatine, the leucine amino acid entity is not HMB;
• wherein, when the composition is in powder form, at least 50 wt. % of the total wt. of the composition is one or more amino acid entities in free form, and
• wherein the total wt. % of (a)-(d) is greater than the total wt. % of other amino acid entities in the composition.